Loading…

Loading grant details…

Active NON-SBIR/STTR RPGS NIH (US)

Engineering the Premetastatic Niche

$5.21M USD

Funder NATIONAL CANCER INSTITUTE
Recipient Organization Purdue University
Country United States
Start Date Sep 01, 2024
End Date Aug 31, 2029
Duration 1,825 days
Number of Grantees 2
Roles Principal Investigator; Co-Investigator
Data Source NIH (US)
Grant ID 10827063
Grant Description

Project Summary The majority of breast cancer related deaths occur as a result of metastasis. Once the cancer cells metastasize, the 5-year relative survival rate for breast cancer patients drastically drops. During metastasis, a complex series of events is initiated by changes in the extracellular matrix (ECM)

composition and architecture in distant tissues, where the metastatic cancer cells take root and form secondary tumors. These distinct changes in the premetastatic niche (PMN) facilitate tumor cell colonization, phenotypic heterogeneity of the cell population, and contribute to drug resistance frequently

observed in metastatic tumors. Using an engineered model of the PMN, we have demonstrated that extracellular vesicles (EVs) facilitate dynamic changes in premetastatic tissues, and that blocking key events during PMN formation disrupts the metastatic process. Our preliminary studies indicate that ECM

proteins transglutaminase 2 (TG2) and fibronectin (FN) play a significant role in establishing the PMN through an EV-dependent mechanism. However, fundamental gaps remain in identifying critical events within the niche that facilitate metastatic colonization of tumor cells, cellular plasticity, and drug

resistance. The overall goal of this proposal is to identify how the dynamic changes within the metastatic niche make the distant tissues hospitable to metastatic cancer cells. Aim 1 will use our novel model of the PMN to identify how specific changes in the PMN facilitate colonization by disseminating cells. Aim

2 is focused on isolating specific effects of ECM dynamics and cellular constituents within the PMN that impact phenotypic heterogeneity and immunogenicity, giving rise to growth permissive and grow restrictive environments. Aim 3 will identify mechanisms by which key matrix components within the niche

protect metastatic tumor cells from therapeutic agents. Our cross-disciplinary team encompasses expertise in biomedical engineering, metastasis, imaging, and EV biology. The proposed studies will establish novel mechanisms by which the PMN facilitates breast cancer metastasis, an essential step towards successful treatments to disrupt the metastatic process.

All Grantees

Purdue University

Advertisement
Apply for grants with GrantFunds
Advertisement
Browse Grants on GrantFunds
Interested in applying for this grant?

Complete our application form to express your interest and we'll guide you through the process.

Apply for This Grant